Eli Lilly transformed from a traditional insulin maker into a pharmaceutical giant, driven by its obesity drug Tirzepatide, sold as Mounjaro and Zepbound. These drugs generated $14.9 billion in Q2 2026 alone, capturing 60% of U.S. obesity prescriptions and boosting international sales significantly. Over 10 years, a $1,000 investment in Eli Lilly grew to $18,637, outperforming the S&P 500 by more than five times. The company continues to expand with new drug approvals and manufacturing plants, though pricing pressures remain a risk as it prepares to file for approval of retatrutide in early 2027.
Eli Lilly's stock price stands at USD 1,252.00 on Pluang as of Oct 17, 2026 01:31 WIB, showing a slight 0.03% increase in the past day. The company holds a market cap of $1.12 trillion and an enterprise value of $1.16 trillion, reflecting its massive scale in the health sector. This strong market presence aligns with the article's highlight of Eli Lilly's impressive growth driven by its obesity drugs.
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor websi...
New data from Eli Lilly reveal that Omvoh (mirikizumab-mrkz) effectively achieves comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year of treatment. These outcomes, observed even...
Sangamo Therapeutics has initiated an auction process for its ST-503 program, a clinical-stage treatment targeting chronic neuropathic pain from small fiber neuropathy, with completion expected in Q4 2026. The program has FDA Fast Track status and sh...
Eli Lilly trades at a premium 24x forward earnings but shows revenue growth of 47.7% year-over-year, far surpassing major pharma peers like Novo Nordisk and AbbVie. The company raised its 2026 revenue guidance twice, aiming for $85B-$87B, driven by s...
